Insmed Sees Unusually High Options Volume (NASDAQ:INSM)

Insmed, Inc. (NASDAQ:INSM) was the target of unusually large options trading on Tuesday. Stock traders bought 8,177 call options on the company. This represents an increase of 206% compared to the typical daily volume of 2,676 call options.

Insmed News Summary

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: New respiratory data could strengthen the pipeline outlook. Insmed will present data at CHEST 2026 and IDWeek 2026 covering treprostinil palmitil inhalation powder (TPIP) in pulmonary hypertension, additional ASPEN bronchiectasis analyses, and ENCORE findings on resistance in MAC lung disease. The presentations could provide investors with additional evidence regarding the commercial potential of Insmed’s respiratory portfolio. Insmed respiratory portfolio data announcement
• Positive Sentiment: HC Wainwright raised its earnings forecasts and maintained a Buy rating. The firm increased its 2026 EPS estimate to a loss of $1.26 from a projected loss of $1.86, raised its fourth-quarter estimate to a loss of $0.08 from $0.49, and lifted its third-quarter estimate to a loss of $0.13 from $0.31. It also modestly increased its 2027 EPS forecast to $1.63. HC Wainwright retained a $220 price target. HC Wainwright Insmed estimates
• Neutral Sentiment: Options activity was unusually heavy. Traders purchased 8,177 call options, more than triple typical daily call volume. This may indicate increased speculative interest or expectations for a move, but it does not establish a clear direction for the shares.
• Negative Sentiment: Wolfe Research downgraded Insmed to Peer Perform from Outperform. The rating change likely contributed to recent weakness by reducing bullish analyst support and signaling that the stock’s risk-reward profile may be less attractive after its prior gains. Insmed Wolfe Research downgrade

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on INSM shares. Roth Capital restated a “buy” rating and issued a $198.00 target price (down from $212.00) on shares of Insmed in a research note on Tuesday, September 15th. Evercore reiterated an “outperform” rating and set a $170.00 price target on shares of Insmed in a research report on Friday, August 7th. Jefferies Financial Group reiterated a “buy” rating and set a $175.00 price target on shares of Insmed in a research report on Thursday, August 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $235.00 price objective on shares of Insmed in a report on Tuesday, July 28th. Finally, UBS Group reissued a “buy” rating on shares of Insmed in a report on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $200.30.

Insider Buying and Selling

In related news, Director David Brennan sold 25,000 shares of the stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the sale, the director directly owned 39,238 shares in the company, valued at $4,865,512. This represents a 38.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Roger Adsett sold 239,850 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $133.27, for a total value of $31,964,809.50. Following the sale, the chief operating officer directly owned 98,744 shares of the company’s stock, valued at $13,159,612.88. This represents a 70.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 2.10% of the stock is owned by corporate insiders.

Institutional Trading of Insmed

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sei Investments Co. grew its position in shares of Insmed by 56.8% during the 1st quarter. Sei Investments Co. now owns 1,395,794 shares of the biopharmaceutical company’s stock worth $228,239,000 after buying an additional 505,624 shares during the period. Castle Hook Partners LP raised its position in shares of Insmed by 14.9% in the 4th quarter. Castle Hook Partners LP now owns 1,253,568 shares of the biopharmaceutical company’s stock valued at $218,171,000 after acquiring an additional 162,163 shares during the period. Pictet Asset Management Holding SA raised its position in shares of Insmed by 14.9% in the 1st quarter. Pictet Asset Management Holding SA now owns 1,102,248 shares of the biopharmaceutical company’s stock valued at $178,659,000 after acquiring an additional 143,285 shares during the period. NWI Management LP raised its position in shares of Insmed by 2.6% in the 1st quarter. NWI Management LP now owns 1,014,000 shares of the biopharmaceutical company’s stock valued at $165,809,000 after acquiring an additional 25,540 shares during the period. Finally, Principal Financial Group Inc. boosted its stake in Insmed by 18.8% during the 1st quarter. Principal Financial Group Inc. now owns 916,464 shares of the biopharmaceutical company’s stock worth $149,860,000 after acquiring an additional 145,106 shares during the last quarter.

Insmed Stock Up 1.0%

Shares of INSM opened at $97.79 on Thursday. The company has a current ratio of 3.72, a quick ratio of 3.40 and a debt-to-equity ratio of 0.74. The business’s fifty day moving average price is $120.14 and its two-hundred day moving average price is $118.75. Insmed has a 52 week low of $90.39 and a 52 week high of $212.75.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.61. The company had revenue of $425.49 million during the quarter, compared to analysts’ expectations of $395.50 million. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%. The business’s revenue for the quarter was up 296.1% on a year-over-year basis. During the same period last year, the firm earned ($1.70) EPS. As a group, equities analysts forecast that Insmed will post -1.72 EPS for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company’s research and development activities center on pulmonary and inflammatory conditions, with an emphasis on diseases that have limited treatment options.

Insmed’s principal commercial product is ARIKAYCE liposomal, an inhaled formulation of amikacin used with a combination antibacterial regimen to treat refractory Mycobacterium avium complex lung disease in certain adult patients.